In xenograft mouse models, TIM-3 blockade led to a significant reduction in leukemic burden and eliminated LSCs making it an attractive target for the treatment of AML and HR-MDS [94]. This evidence concerns the gene HAVCR2 and myelodysplastic syndrome.